Literature DB >> 30804488

Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission.

Colin D Godwin1, Jonathan R Fromm2, Megan Othus3, Brenda M Sandmaier4,5, Marco B Mielcarek4,5, Brent L Wood2, Frederick R Appelbaum4,5, Rainer Storb4,5, Roland B Walter4,5,6,7.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30804488      PMCID： PMC6708776          DOI： 10.1038/s41409-019-0481-9

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.

Authors:  Roland B Walter; Ted A Gooley; Brent L Wood; Filippo Milano; Min Fang; Mohamed L Sorror; Elihu H Estey; Alexander I Salter; Emily Lansverk; Jason W Chien; Ajay K Gopal; Frederick R Appelbaum; John M Pagel
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

2.  Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia.

Authors:  Hui Sun; Yi Li; Zhi-fen Zhang; Ying Ju; Li Li; Bing-chang Zhang; Bin Liu
Journal:  Int J Hematol       Date:  2015-09-10       Impact factor: 2.490

3.  MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia.

Authors:  Athalia Rachel Pyzer; Dina Stroopinsky; Hasan Rajabi; Abigail Washington; Ashujit Tagde; Maxwell Coll; Jacqueline Fung; Mary Paty Bryant; Leandra Cole; Kristen Palmer; Poorvi Somaiya; Rebecca Karp Leaf; Myrna Nahas; Arie Apel; Salvia Jain; Malgorzata McMasters; Lourdes Mendez; James Levine; Robin Joyce; Jon Arnason; Pier Paolo Pandolfi; Donald Kufe; Jacalyn Rosenblatt; David Avigan
Journal:  Blood       Date:  2017-01-26       Impact factor: 22.113

4.  Tumor-induced CD14+HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients.

Authors:  Zhitao Wang; Lulu Zhang; Huiping Wang; Shudao Xiong; Yanli Li; Qianshan Tao; Weihua Xiao; Hui Qin; Yiping Wang; Zhimin Zhai
Journal:  Cancer Immunol Immunother       Date:  2014-12-30       Impact factor: 6.968

Review 5.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

Review 6.  Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer.

Authors:  Salman M Toor; Eyad Elkord
Journal:  Immunol Cell Biol       Date:  2018-04-22       Impact factor: 5.126

7.  Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia.

Authors:  R B Walter; M Othus; E M Paietta; J Racevskis; H F Fernandez; J-W Lee; Z Sun; M S Tallman; J Patel; M Gönen; O Abdel-Wahab; R L Levine; E H Estey
Journal:  Leukemia       Date:  2015-03-16       Impact factor: 11.528

8.  Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center.

Authors:  R B Walter; M Othus; A K Burnett; B Löwenberg; H M Kantarjian; G J Ossenkoppele; R K Hills; F Ravandi; T Pabst; A Evans; S R Pierce; M-C Vekemans; F R Appelbaum; E H Estey
Journal:  Leukemia       Date:  2014-08-12       Impact factor: 11.528

9.  Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.

Authors:  Ahmad A Tarhini; Howard Edington; Lisa H Butterfield; Yan Lin; Yongli Shuai; Hussein Tawbi; Cindy Sander; Yan Yin; Matthew Holtzman; Jonas Johnson; Uma N M Rao; John M Kirkwood
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

10.  Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation.

Authors:  R B Walter; B Gyurkocza; B E Storer; C D Godwin; J M Pagel; S A Buckley; M L Sorror; B L Wood; R Storb; F R Appelbaum; B M Sandmaier
Journal:  Leukemia       Date:  2014-06-03       Impact factor: 11.528
View more
  1 in total

Review 1.  Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy.

Authors:  Sophia Khaldoyanidi; Dirk Nagorsen; Anthony Stein; Gerrit Ossenkoppele; Marion Subklewe
Journal:  J Clin Oncol       Date:  2021-01-12       Impact factor: 44.544
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.